Share Price and Basic Stock Data
Last Updated: December 24, 2025, 4:23 pm
| PEG Ratio | -22.52 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Arvee Laboratories (India) Ltd operates in the specialty chemicals sector, focusing on various chemical products. The company recorded sales of ₹61.35 Cr for the financial year ending March 2023, a notable increase from ₹40.33 Cr in March 2022. However, sales have displayed volatility, with quarterly figures showing a decline to ₹7.60 Cr in June 2023 and fluctuating between ₹6.14 Cr to ₹12.56 Cr in the subsequent quarters. The trailing twelve months (TTM) sales stood at ₹26.29 Cr, indicating a downward trend compared to previous years. The company’s operating profit margin (OPM) was 4.55% as of the latest reporting period, which is relatively low compared to typical sector averages, reflecting challenges in maintaining profitability amid fluctuating revenues. Despite the sales decline in recent quarters, the company has consistently reported revenues exceeding ₹30 Cr in prior years, demonstrating its potential for recovery and growth in a recovering market.
Profitability and Efficiency Metrics
Arvee Laboratories reported a net profit of ₹4.12 Cr for FY 2023, a significant increase from ₹2.57 Cr in FY 2022. However, the net profit margin stood at 6.71% for the same period, which is below the industry average, indicating room for improvement in cost management. The company’s return on equity (ROE) was recorded at 7.12%, while the return on capital employed (ROCE) stood at 10.00%, suggesting moderate efficiency in generating returns from investments. Additionally, the interest coverage ratio (ICR) was a robust 17.19, showcasing the company’s ability to meet interest obligations comfortably. However, the cash conversion cycle (CCC) extended to 102.25 days, indicating potential inefficiencies in managing inventory and receivables. This prolonged cycle could impact liquidity and operational efficiency, posing a risk to profitability if not addressed effectively.
Balance Sheet Strength and Financial Ratios
As of March 2025, Arvee Laboratories reported total borrowings of ₹1.03 Cr against reserves of ₹20.42 Cr, indicating a strong capital structure with low debt levels. The total liabilities stood at ₹38.16 Cr, while total assets were ₹38.16 Cr, reflecting a balanced sheet with no significant leverage issues. The company’s price-to-book value (P/BV) ratio is at 5.01x, suggesting that the stock is trading at a premium relative to its book value, which was recorded at ₹28.37 per share. The current ratio of 5.14 indicates strong liquidity, allowing the company to cover its short-term obligations effectively. In contrast, the inventory turnover ratio stood at 7.03, which is relatively high, reflecting efficient inventory management practices. However, the decline in profitability ratios, such as the net profit margin and operating profit margin, raises concerns about the sustainability of these financial strengths amidst fluctuating sales performance.
Shareholding Pattern and Investor Confidence
Arvee Laboratories maintains a stable shareholding structure, with promoters holding 73.50% of the equity as of the latest reporting period. This significant promoter stake suggests strong confidence and commitment from the management team. Public shareholding stands at 26.50%, with a total of 1,505 shareholders recorded in the most recent quarter, reflecting a gradual increase in shareholder participation. The number of shareholders has grown from 864 in March 2023 to 1,505 in June 2025, indicating rising interest in the company’s prospects. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may limit broader market confidence and liquidity. This concentrated ownership can be both a strength, in terms of stable management control, and a risk, as it may deter institutional investment that often seeks diversified ownership to mitigate risks.
Outlook, Risks, and Final Insight
The outlook for Arvee Laboratories hinges on its ability to stabilize revenue streams and enhance profitability. The company’s low debt levels and strong liquidity position provide a solid foundation for potential growth initiatives. However, the risks include ongoing volatility in sales, as evidenced by recent quarterly performance, and the need for better inventory and receivables management to reduce the cash conversion cycle. If the company can implement effective operational changes and capitalize on market opportunities, it may regain its previous growth trajectory. Conversely, continued sales decline or inability to manage costs could exacerbate profitability challenges. In conclusion, while Arvee Laboratories has certain financial strengths, addressing operational inefficiencies and market volatility will be crucial for sustained growth and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 400 Cr. | 43.5 | 83.5/41.2 | 24.8 | 20.5 | 0.92 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.2 Cr. | 63.5 | 91.9/56.0 | 14.9 | 89.6 | 1.57 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.6 Cr. | 730 | 935/600 | 22.9 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,406 Cr. | 75.1 | 111/74.0 | 22.6 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 651 Cr. | 261 | 393/241 | 23.4 | 93.8 | 0.96 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,792.36 Cr | 727.35 | 71.43 | 183.02 | 0.44% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.18 | 22.74 | 16.25 | 12.56 | 7.60 | 8.91 | 7.70 | 6.14 | 10.60 | 12.53 | 8.91 | 6.45 | 7.48 |
| Expenses | 15.92 | 19.48 | 14.51 | 11.40 | 6.62 | 8.22 | 7.17 | 5.35 | 9.06 | 11.03 | 8.57 | 6.23 | 7.14 |
| Operating Profit | 2.26 | 3.26 | 1.74 | 1.16 | 0.98 | 0.69 | 0.53 | 0.79 | 1.54 | 1.50 | 0.34 | 0.22 | 0.34 |
| OPM % | 12.43% | 14.34% | 10.71% | 9.24% | 12.89% | 7.74% | 6.88% | 12.87% | 14.53% | 11.97% | 3.82% | 3.41% | 4.55% |
| Other Income | 0.02 | 0.06 | 0.07 | 0.06 | 0.09 | 0.09 | 0.19 | 0.21 | 0.11 | 0.16 | 0.19 | 0.21 | 0.17 |
| Interest | 0.11 | 0.11 | 0.09 | 0.07 | 0.07 | 0.08 | 0.05 | 0.05 | 0.08 | 0.05 | 0.05 | 0.07 | 0.04 |
| Depreciation | 0.64 | 0.48 | 0.49 | 0.48 | 0.35 | 0.42 | 0.35 | 0.37 | 0.31 | 0.30 | 0.28 | 0.27 | 0.29 |
| Profit before tax | 1.53 | 2.73 | 1.23 | 0.67 | 0.65 | 0.28 | 0.32 | 0.58 | 1.26 | 1.31 | 0.20 | 0.09 | 0.18 |
| Tax % | 24.84% | 25.27% | 25.20% | 100.00% | 24.62% | 25.00% | 25.00% | 81.03% | 25.40% | 25.19% | 25.00% | 22.22% | 5.56% |
| Net Profit | 1.14 | 2.05 | 0.92 | 0.01 | 0.49 | 0.21 | 0.24 | 0.12 | 0.94 | 0.98 | 0.15 | 0.07 | 0.17 |
| EPS in Rs | 1.03 | 1.86 | 0.83 | 0.01 | 0.44 | 0.19 | 0.22 | 0.11 | 0.85 | 0.89 | 0.14 | 0.06 | 0.15 |
Last Updated: August 20, 2025, 1:35 pm
Below is a detailed analysis of the quarterly data for Arvee Laboratories (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 7.48 Cr.. The value appears strong and on an upward trend. It has increased from 6.45 Cr. (Mar 2025) to 7.48 Cr., marking an increase of 1.03 Cr..
- For Expenses, as of Jun 2025, the value is 7.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.23 Cr. (Mar 2025) to 7.14 Cr., marking an increase of 0.91 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.34 Cr., marking an increase of 0.12 Cr..
- For OPM %, as of Jun 2025, the value is 4.55%. The value appears strong and on an upward trend. It has increased from 3.41% (Mar 2025) to 4.55%, marking an increase of 1.14%.
- For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 0.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.27 Cr. (Mar 2025) to 0.29 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 0.18 Cr., marking an increase of 0.09 Cr..
- For Tax %, as of Jun 2025, the value is 5.56%. The value appears to be improving (decreasing) as expected. It has decreased from 22.22% (Mar 2025) to 5.56%, marking a decrease of 16.66%.
- For Net Profit, as of Jun 2025, the value is 0.17 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Mar 2025) to 0.17 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.15. The value appears strong and on an upward trend. It has increased from 0.06 (Mar 2025) to 0.15, marking an increase of 0.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:38 am
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 | 40.33 | 61.35 | 30.35 | 38.49 | 26.29 |
| Expenses | 21.83 | 28.54 | 40.61 | 48.73 | 39.40 | 41.31 | 34.65 | 54.06 | 27.41 | 34.88 | 25.27 |
| Operating Profit | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 | 5.68 | 7.29 | 2.94 | 3.61 | 1.02 |
| OPM % | 18.61% | 17.13% | 15.01% | 11.24% | 13.25% | 12.81% | 14.08% | 11.88% | 9.69% | 9.38% | 3.88% |
| Other Income | 0.10 | 0.51 | 0.23 | 0.35 | 0.35 | 0.56 | 0.46 | 1.35 | 0.64 | 0.66 | 0.80 |
| Interest | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 | 0.37 | 0.39 | 0.25 | 0.25 | 0.20 |
| Depreciation | 1.49 | 2.07 | 2.15 | 2.35 | 2.29 | 2.41 | 2.32 | 2.08 | 1.50 | 1.15 | 1.14 |
| Profit before tax | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 | 3.45 | 6.17 | 1.83 | 2.87 | 0.48 |
| Tax % | 66.04% | -81.40% | 43.23% | 11.02% | 25.89% | 26.37% | 25.51% | 33.23% | 42.62% | 25.09% | |
| Net Profit | 0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 | 2.57 | 4.12 | 1.05 | 2.15 | 0.40 |
| EPS in Rs | 0.23 | 1.91 | 0.99 | 2.05 | 2.09 | 2.43 | 2.33 | 3.74 | 0.95 | 1.95 | 0.36 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 715.79% | -29.68% | 107.34% | 1.77% | 16.52% | -4.10% | 60.31% | -74.51% | 104.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -745.47% | 137.02% | -105.57% | 14.75% | -20.63% | 64.42% | -134.83% | 179.28% |
Arvee Laboratories (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 22% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 7% |
Last Updated: September 4, 2025, 11:40 pm
Balance Sheet
Last Updated: December 10, 2025, 2:23 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.05 | 4.05 | 5.51 | 5.51 | 5.51 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
| Reserves | -1.41 | 0.15 | 8.69 | 10.95 | 13.25 | 10.42 | 12.92 | 17.04 | 18.09 | 20.24 | 20.42 |
| Borrowings | 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | 1.03 | 1.03 |
| Other Liabilities | 7.25 | 6.49 | 13.77 | 7.81 | 11.00 | 10.73 | 11.61 | 9.63 | 8.08 | 5.87 | 8.11 |
| Total Liabilities | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
| Fixed Assets | 13.15 | 16.88 | 14.88 | 12.65 | 13.18 | 13.81 | 13.84 | 12.68 | 12.67 | 15.27 | 15.25 |
| CWIP | 4.30 | 0.00 | 1.18 | 2.32 | 1.78 | 0.97 | 0.98 | 1.53 | 2.62 | 0.73 | 0.81 |
| Investments | 0.00 | 0.00 | 0.00 | 1.95 | 3.09 | 2.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 17.76 | 18.80 | 28.06 | 20.22 | 15.58 | 24.24 | 23.86 | 24.48 | 22.90 | 22.16 | 24.52 |
| Total Assets | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
Below is a detailed analysis of the balance sheet data for Arvee Laboratories (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.02 Cr..
- For Reserves, as of Sep 2025, the value is 20.42 Cr.. The value appears strong and on an upward trend. It has increased from 20.24 Cr. (Mar 2025) to 20.42 Cr., marking an increase of 0.18 Cr..
- For Borrowings, as of Sep 2025, the value is 1.03 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 1.03 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.87 Cr. (Mar 2025) to 8.11 Cr., marking an increase of 2.24 Cr..
- For Total Liabilities, as of Sep 2025, the value is 40.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.16 Cr. (Mar 2025) to 40.58 Cr., marking an increase of 2.42 Cr..
- For Fixed Assets, as of Sep 2025, the value is 15.25 Cr.. The value appears to be declining and may need further review. It has decreased from 15.27 Cr. (Mar 2025) to 15.25 Cr., marking a decrease of 0.02 Cr..
- For CWIP, as of Sep 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.73 Cr. (Mar 2025) to 0.81 Cr., marking an increase of 0.08 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 24.52 Cr.. The value appears strong and on an upward trend. It has increased from 22.16 Cr. (Mar 2025) to 24.52 Cr., marking an increase of 2.36 Cr..
- For Total Assets, as of Sep 2025, the value is 40.58 Cr.. The value appears strong and on an upward trend. It has increased from 38.16 Cr. (Mar 2025) to 40.58 Cr., marking an increase of 2.42 Cr..
Notably, the Reserves (20.42 Cr.) exceed the Borrowings (1.03 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.33 | -19.09 | -8.98 | -6.70 | 2.15 | -2.81 | 2.55 | 6.29 | 1.94 | 2.58 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82.61 | 87.12 | 118.25 | 52.66 | 52.40 | 60.70 | 109.78 | 72.94 | 73.48 | 79.66 |
| Inventory Days | 155.08 | 104.53 | 99.61 | 42.90 | 80.96 | 91.96 | 93.24 | 42.29 | 159.02 | 80.31 |
| Days Payable | 130.73 | 98.14 | 150.03 | 55.84 | 125.63 | 118.08 | 160.12 | 73.30 | 164.49 | 57.72 |
| Cash Conversion Cycle | 106.96 | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.01 | 102.25 |
| Working Capital Days | 30.08 | 30.84 | 30.79 | -6.52 | 10.29 | -10.63 | 49.96 | 70.44 | 95.97 | 106.59 |
| ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 6.83% | 10.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Diluted EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Cash EPS (Rs.) | 2.99 | 2.31 | 5.63 | 4.44 | 4.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Revenue From Operations / Share (Rs.) | 34.92 | 27.54 | 55.67 | 36.59 | 42.99 |
| PBDIT / Share (Rs.) | 3.87 | 3.25 | 7.83 | 5.56 | 6.01 |
| PBIT / Share (Rs.) | 2.83 | 1.89 | 5.95 | 3.46 | 3.83 |
| PBT / Share (Rs.) | 2.61 | 1.66 | 5.59 | 3.13 | 3.30 |
| Net Profit / Share (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| PBDIT Margin (%) | 11.08 | 11.78 | 14.07 | 15.19 | 13.98 |
| PBIT Margin (%) | 8.10 | 6.85 | 10.68 | 9.44 | 8.90 |
| PBT Margin (%) | 7.45 | 6.02 | 10.04 | 8.55 | 7.68 |
| Net Profit Margin (%) | 5.57 | 3.46 | 6.71 | 6.38 | 5.65 |
| Return on Networth / Equity (%) | 6.86 | 3.61 | 14.67 | 10.75 | 12.48 |
| Return on Capital Employeed (%) | 9.24 | 6.65 | 21.95 | 15.14 | 18.53 |
| Return On Assets (%) | 5.71 | 2.75 | 10.64 | 6.65 | 6.52 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
| Total Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.13 | 0.41 |
| Asset Turnover Ratio (%) | 1.02 | 0.78 | 1.59 | 1.01 | 1.27 |
| Current Ratio (X) | 5.14 | 2.42 | 2.44 | 1.75 | 1.40 |
| Quick Ratio (X) | 3.95 | 1.50 | 1.92 | 1.33 | 0.99 |
| Inventory Turnover Ratio (X) | 7.03 | 3.08 | 7.48 | 3.53 | 4.18 |
| Interest Coverage Ratio (X) | 17.19 | 14.34 | 22.25 | 17.08 | 11.49 |
| Interest Coverage Ratio (Post Tax) (X) | 9.65 | 5.22 | 11.62 | 8.17 | 5.64 |
| Enterprise Value (Cr.) | 152.60 | 157.16 | 97.08 | 123.80 | 63.32 |
| EV / Net Operating Revenue (X) | 3.96 | 5.18 | 1.58 | 3.07 | 1.34 |
| EV / EBITDA (X) | 35.75 | 43.93 | 11.25 | 20.20 | 9.56 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| Price / BV (X) | 5.01 | 5.43 | 3.46 | 5.23 | 2.85 |
| Price / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| EarningsYield | 0.01 | 0.01 | 0.04 | 0.02 | 0.04 |
After reviewing the key financial ratios for Arvee Laboratories (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 2.31 (Mar 24) to 2.99, marking an increase of 0.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 34.92. It has increased from 27.54 (Mar 24) to 34.92, marking an increase of 7.38.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.87. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 3.87, marking an increase of 0.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.83, marking an increase of 0.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.66 (Mar 24) to 2.61, marking an increase of 0.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 2. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For PBDIT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 11.08, marking a decrease of 0.70.
- For PBIT Margin (%), as of Mar 25, the value is 8.10. This value is below the healthy minimum of 10. It has increased from 6.85 (Mar 24) to 8.10, marking an increase of 1.25.
- For PBT Margin (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 10. It has increased from 6.02 (Mar 24) to 7.45, marking an increase of 1.43.
- For Net Profit Margin (%), as of Mar 25, the value is 5.57. This value is within the healthy range. It has increased from 3.46 (Mar 24) to 5.57, marking an increase of 2.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.86. This value is below the healthy minimum of 15. It has increased from 3.61 (Mar 24) to 6.86, marking an increase of 3.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.24. This value is below the healthy minimum of 10. It has increased from 6.65 (Mar 24) to 9.24, marking an increase of 2.59.
- For Return On Assets (%), as of Mar 25, the value is 5.71. This value is within the healthy range. It has increased from 2.75 (Mar 24) to 5.71, marking an increase of 2.96.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.02. It has increased from 0.78 (Mar 24) to 1.02, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 5.14. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 5.14, marking an increase of 2.72.
- For Quick Ratio (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.95, marking an increase of 2.45.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.03. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 7.03, marking an increase of 3.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.19. This value is within the healthy range. It has increased from 14.34 (Mar 24) to 17.19, marking an increase of 2.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.65. This value is within the healthy range. It has increased from 5.22 (Mar 24) to 9.65, marking an increase of 4.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 152.60. It has decreased from 157.16 (Mar 24) to 152.60, marking a decrease of 4.56.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.96. This value exceeds the healthy maximum of 3. It has decreased from 5.18 (Mar 24) to 3.96, marking a decrease of 1.22.
- For EV / EBITDA (X), as of Mar 25, the value is 35.75. This value exceeds the healthy maximum of 15. It has decreased from 43.93 (Mar 24) to 35.75, marking a decrease of 8.18.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For Price / BV (X), as of Mar 25, the value is 5.01. This value exceeds the healthy maximum of 3. It has decreased from 5.43 (Mar 24) to 5.01, marking a decrease of 0.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Arvee Laboratories (India) Ltd:
- Net Profit Margin: 5.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.24% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.86% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.95
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 702 (Industry average Stock P/E: 71.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 403, Entice, Nr. Jayantilal Park BRTS, Ahmedabad Gujarat 380058 | compliance@arveelabs.com http://www.arveelabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shalin Sudhakarbhai Patel | Managing Director |
| Mr. Shalin Bharat Chokshi | Whole Time Director |
| Mrs. Neetu Rishi Jalan | Ind.& Non Exe.Director |
| Mr. Sachin Kanwarlal Kansal | Ind.& Non Exe.Director |
| Ms. Shalini Hitesh Jalan | Ind.& Non Exe.Director |
FAQ
What is the intrinsic value of Arvee Laboratories (India) Ltd?
Arvee Laboratories (India) Ltd's intrinsic value (as of 25 December 2025) is 1162.39 which is 355.84% higher the current market price of 255.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 281 Cr. market cap, FY2025-2026 high/low of 291/127, reserves of ₹20.42 Cr, and liabilities of 40.58 Cr.
What is the Market Cap of Arvee Laboratories (India) Ltd?
The Market Cap of Arvee Laboratories (India) Ltd is 281 Cr..
What is the current Stock Price of Arvee Laboratories (India) Ltd as on 25 December 2025?
The current stock price of Arvee Laboratories (India) Ltd as on 25 December 2025 is 255.
What is the High / Low of Arvee Laboratories (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Arvee Laboratories (India) Ltd stocks is 291/127.
What is the Stock P/E of Arvee Laboratories (India) Ltd?
The Stock P/E of Arvee Laboratories (India) Ltd is 702.
What is the Book Value of Arvee Laboratories (India) Ltd?
The Book Value of Arvee Laboratories (India) Ltd is 28.5.
What is the Dividend Yield of Arvee Laboratories (India) Ltd?
The Dividend Yield of Arvee Laboratories (India) Ltd is 0.00 %.
What is the ROCE of Arvee Laboratories (India) Ltd?
The ROCE of Arvee Laboratories (India) Ltd is 10.0 %.
What is the ROE of Arvee Laboratories (India) Ltd?
The ROE of Arvee Laboratories (India) Ltd is 7.12 %.
What is the Face Value of Arvee Laboratories (India) Ltd?
The Face Value of Arvee Laboratories (India) Ltd is 10.0.